123 related articles for article (PubMed ID: 27266997)
1. Design and synthesis of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides as novel Hsp90 inhibitors.
Liang C; Hao H; Wu X; Li Z; Zhu J; Lu C; Shen Y
Eur J Med Chem; 2016 Oct; 121():272-282. PubMed ID: 27266997
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and pharmacological evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors.
Liang C; Wu X; Li Z; Zhu J; Lu C; Shen Y
Eur J Med Chem; 2018 Jan; 143():85-96. PubMed ID: 29172085
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Hao H; Xu H; Wu Y; Shi G; Lu C; Shen Y
Eur J Med Chem; 2014 Oct; 85():359-70. PubMed ID: 25105924
[TBL] [Abstract][Full Text] [Related]
4. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors.
Suda A; Kawasaki K; Komiyama S; Isshiki Y; Yoon DO; Kim SJ; Na YJ; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
Bioorg Med Chem; 2014 Jan; 22(2):892-905. PubMed ID: 24369839
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis.
Koca İ; Özgür A; Er M; Gümüş M; Açikalin Coşkun K; Tutar Y
Eur J Med Chem; 2016 Oct; 122():280-290. PubMed ID: 27376491
[TBL] [Abstract][Full Text] [Related]
7. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y
Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of neolamellarin a derivatives targeting heat shock protein 90.
Jiang L; Yin R; Wang X; Dai J; Li J; Jiang T; Yu R
Eur J Med Chem; 2017 Jul; 135():24-33. PubMed ID: 28426997
[TBL] [Abstract][Full Text] [Related]
9. Identification of New Hsp90 Inhibitors: Structure Based Virtual Screening, Molecular Dynamic Simulation, Synthesis and Biological Evaluation.
Abbasi M; Amanlou M; Aghaei M; Hassanzadeh F; Sadeghi-Aliabadi H
Anticancer Agents Med Chem; 2021; 21(18):2583-2591. PubMed ID: 33563187
[TBL] [Abstract][Full Text] [Related]
10. Binding of natural and synthetic inhibitors to human heat shock protein 90 and their clinical application.
Petrikaitė V; Matulis D
Medicina (Kaunas); 2011; 47(8):413-20. PubMed ID: 22123555
[TBL] [Abstract][Full Text] [Related]
11. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
12. Identification and Structure-Activity Studies of 1,3-Dibenzyl-2-aryl imidazolidines as Novel Hsp90 Inhibitors.
Liu Y; Liu X; Li L; Dai R; Shi M; Xue H; Liu Y; Wang H
Molecules; 2019 Jun; 24(11):. PubMed ID: 31163701
[TBL] [Abstract][Full Text] [Related]
13. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of 3,5-disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors.
Sun J; Lin C; Qin X; Dong X; Tu Z; Tang F; Chen C; Zhang J
Bioorg Med Chem Lett; 2015 Aug; 25(16):3129-34. PubMed ID: 26112442
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.
Chang DJ; An H; Kim KS; Kim HH; Jung J; Lee JM; Kim NJ; Han YT; Yun H; Lee S; Lee G; Lee S; Lee JS; Cha JH; Park JH; Park JW; Lee SC; Kim SG; Kim JH; Lee HY; Kim KW; Suh YG
J Med Chem; 2012 Dec; 55(24):10863-84. PubMed ID: 23186287
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking study, synthesis and biological evaluation of Mannich bases as Hsp90 inhibitors.
Dutta Gupta S; Bommaka MK; Mazaira GI; Galigniana MD; Subrahmanyam CV; Gowrishankar NL; Raghavendra NM
Int J Biol Macromol; 2015 Sep; 80():253-9. PubMed ID: 26116388
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors.
Suda A; Koyano H; Hayase T; Hada K; Kawasaki K; Komiyama S; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
Bioorg Med Chem Lett; 2012 Jan; 22(2):1136-41. PubMed ID: 22192591
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors.
Zhang X; Zhang J; Zhang L; Feng J; Xu Y; Yuan Y; Fang H; Xu W
Bioorg Med Chem; 2011 Oct; 19(20):6015-25. PubMed ID: 21911297
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of 4-(1H-1,2,3-triazol-1-yl)benzamides as HSP90 inhibitors.
He T; Zhu S; Lu W
Mol Divers; 2023 Feb; 27(1):239-248. PubMed ID: 35429283
[TBL] [Abstract][Full Text] [Related]
20. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
